Immunitybio is trading 4.52% down now at $8.02 as biotechnology stocks weaken amid rate uncertainty surrounding Federal Reserve Chair Kevin Warsh’s Jackson Hole speech.
- The sector’s risk-off move appears to be pressuring Immunitybio.
- Warsh’s remarks were associated with higher short-term Treasury yields and cautious stock trading, reinforcing pressure on rate-sensitive growth sectors.
- No fresh company-specific announcement was identified for August 28, 2026.